Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma

Glaubiger, Daniel; Makuch, Robert W.; Schwarz, Janet E.; Levine, Arthur S.; Johnson, Ralph E.

doi:10.1002/1097-0142(19800415)45:8<2213::aid-cncr2820450834>3.0.co;2-l

Cited by 83 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Egger's test (19,20,(22)(23)(24)(25). The funnel plot for this meta-analysis revealed evidence of symmetry, and the P-value from the Egger's test was 0.707 in the OS studies (Fig.…”

Section: Meta-analysismentioning

confidence: 78%

See 1 more Smart Citation

Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

Yang

Wang

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract.A number of studies have investigated the role of serum lactate dehydrogenase (LDH) levels in patients with Ewing's sarcoma, although these have yielded inconsistent and inconclusive results. Therefore, the present study aimed to systematically review the published studies and conduct a meta-analysis to assess its prognostic value more precisely. Cohort studies assessing the prognostic role of LDH levels in patients with Ewing's sarcoma were included. A pooled hazard ratio (HR) with 95% confidence intervals (CIs) of overall survival (OS) or 5-year disease-free survival (DFS) was used to assess the prognostic role of the levels of serum LDH. Nine studies published between 1980 and 2014, with a total of 1,412 patients with Ewing's sarcoma, were included. Six studies, with a total of 644 patients, used OS as the primary endpoint and four studies, with 795 patients, used 5-year DFS. Overall, the pooled HR evaluating high LDH levels was 2.90 (95% CI: 2.09-4.04) for OS and 2.40 (95% CI: 1.93-2.98) for 5-year DFS. This meta-analysis demonstrates that high levels of serum LDH are associated with lower OS and 5-year DFS rates in patients with Ewing's sarcoma. Therefore, serum LDH levels are an effective biomarker of Ewing's sarcoma prognosis.

show abstract

“…Egger's test (19,20,(22)(23)(24)(25). The funnel plot for this meta-analysis revealed evidence of symmetry, and the P-value from the Egger's test was 0.707 in the OS studies (Fig.…”

Section: Meta-analysismentioning

confidence: 78%

“…1 shows a flow diagram of the selection process for defining the relative studies. Following the process of selection, nine studies met the inclusion criteria and were included in the meta-analysis (17)(18)(19)(20)(21)(22)(23)(24)(25). The major characteristics of the nine eligible publications are shown in Table I.…”

Section: Resultsmentioning

confidence: 99%

Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

Yang

Wang

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…[29][30][31] Use of markers in the specific diagnosis of disease have been considered, 32 but the most researched use of tumour markers has been in the development of prognostic risk groups in order to target therapy. [33][34][35][36][37][38] Use of tumour markers in the monitoring of patients following primary therapy has also been considered. 39,40 Rationale for a systematic review of tumour markers in paediatric oncology A persistent difficulty in conducting primary research in paediatric oncology, not just in relation to the use of tumour markers, is the relatively small number of children who develop disease, and the therefore low statistical power which individual primary studies have of detecting either treatment benefits or survival benefits arising out of prognostic staging (using tumour markers).…”

Section: Use Of Tumour Markers In Paediatric Oncologymentioning

confidence: 99%

mentioning

confidence: 99%

A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma

Riley

Burchill

Abrams

et al. 2003

Health Technol Assess

147

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents, York Publishing Services by:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS and public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please contact York Publishing Services at the address above. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to York Publishing Distribution and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.ncchta.org/htacd.htm). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma RD Riley NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent...

show abstract

“…In a review of prognostic factors, the adverse influence of older age, pelvic site and presence of metastatic disease was confirmed (Glaubiger et al, 1980;Craft, 1985). In addition, male gender and increasing tumour volume were identified as possible indicators of poor outcome.…”

mentioning

confidence: 96%

Establishing long-term survival and cure in young patients with Ewing's sarcoma

et al. 2004

View full text Add to dashboard Cite

This paper investigates the potential for long-term survivorship for young patients diagnosed with Ewing's sarcoma. Data are examined from two successive UKCCSG Ewing's Tumour studies (ET-1 and ET-2). Patients have been followed for up to 20 years. These studies had suggested that better 5-year survival with ET-2 over the earlier ET-1 was achieved by replacing cyclophosphamide by ifosfamide and increasing the dose of doxorubicin in a four-drug chemotherapy regimen. The updated hazard ratio, stratified for metastatic status at diagnosis, of 0.39 (95% confidence interval 0.12 -0.61) confirmed the advantage of the ET-2 regimen in terms of overall survival. Cure models, based on the Weibull distribution, suggested that factors for long-term survival in addition to presence of metastases were age, primary site of tumour and study. Modelling identified the proportion cured with the ET-2 protocol as best at 70% in those who are under 10 years with a nonpelvic primary site and without metastatic disease. This contrasts to only 13% cure in those with the corresponding adverse prognostic indicators. Additionally, the risk of death remains greatest but relatively constant over the first 2 years postdiagnosis, and then declines to a lower but constant value for the next 3 years before reaching the 'cure plateau' at about 5 years. This investigation suggests that 'cure' is possible for patients with Ewing's sarcoma. This is established at approximately 5 years post diagnosis and the proportion cured depends on the presence of metastases, pelvic site and age at diagnosis.

show abstract

Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma

Cited by 83 publications

References 15 publications

Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma

Establishing long-term survival and cure in young patients with Ewing's sarcoma

Contact Info

Product

Resources

About